Arctic Bioscience AS will publish its financial results for the first half of 2021 on
Thursday August 26, 2021, at 07:00 CEST. The company will host a webcast
presentation of the results the same day at 08:30 CEST.
Arctic Bioscience AS H1 2021 webcast presentation:
Date: Thursday August 26, 2021
Time: 08:30 a.m. CEST
Format: Webcast and Q&A
This information is subject to the disclosure requirements in EU Market Abuse
Regulations (MAR) 596/2014 article 19 number 3 and the Norwegian Securities
Trading Act § 5-12.
For further information, please contact:
Danielle Glenn, CFO
Mobile: +47 909 98 201
About Arctic Bioscience
Arctic Bioscience is a biotech company developing pharmaceutical and nutraceutical products based on the unique properties of herring roe oil, composed of complex bioactive marine compounds, including lipids essential to maintaining cell membranes. The nutraceutical products contain lipids which contribute to the normal functioning of brain, heart and vision.
The company is developing a novel drug candidate (HRO350) for mild-to-moderate psoriasis, a large global patient population where there is substantial need for effective, convenient and cost-effective new medicines with beneficial safety profiles. Nutraceuticals from Arctic Bioscience are sold worldwide as bulk ingredients to other companies making dietary supplements (B2B) and as finished goods under the ROMEGA™ brand (B2C), with significant expansion potential all channels and regions.
To support its long-term growth strategy, Arctic Bioscience is planning a state-of-the-art manufacturing facility in Ørsta. Easy access to the raw material and proprietary production processes will increase control of the value chain, improve margins and enable large-scale, high-quality manufacturing.
Arctic Bioscience is led by a highly competent team with significant expertise developing marine oils and extensive experience from some of the world’s leading pharmaceutical, technology and financial services companies.